Chiefs Hall of Honor member Art Still is a proud foot soldier in the Amyloidosis Army, a nonprofit he started hoping to ...

Amyloidosis is a rare protein-related condition that occurs when your body produces too many amyloid proteins, causing damage to your organs and tissues. Amyloid proteins are a type of protein ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

Hereditary ATTR amyloidosis (hATTR amyloidosis) is a rare, debilitating disease that runs in families. It's caused by ...

Recent research from Stony Brook Medicine shows that early signs of dementia are becoming more frequent among first ...

Several case reports and retrospective cohort studies have described a marginal benefit with the use of internal cardioverter defibrillators in patients with cardiac amyloidosis. Detection of ...

NEXICART-2 is an open-label study designed to evaluate NXC-201 in patients with R/R AL Amyloidosis. The study has two segments: a six-patient “safety run-in” segment and a 34-patient dose ...

Amvuttra (vutrisiran) is a follow-up to Alnylam's earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler ...

Transthyretin amyloidosis is a progressive, fatal disease that often leads to cardiomyopathy. New research findings on vutrisiran for patients with transthyretin amyloidosis with cardiomyopathy ...